Target intelligence / Profile preview

RNA, 7SL, cytoplasmic 229, pseudogene (RN7SL229P)

Target
RN7SL229P
Molecular classification
Pseudogene, Non-coding RNA (pseudogenic variant), Not classified as receptor, enzyme, transporter, transcription factor, or other canonical drug target family
01

Overview

RN7SL229P is a human pseudogene belonging to the 7SL RNA family. The original 7SL RNA (such as RNA, 7SL, cytoplasmic 1, or RN7SL1) functions as an essential scaffold within the signal recognition particle (SRP), a ribonucleoprotein complex that mediates cotranslational protein targeting to the endoplasmic reticulum[3][5]. However, RN7SL229P, like most 7SL RNA-derived pseudogenes, is a truncated, non-functional copy resulting from the integration of sequence reverse-transcribed from RNA back into the genome[1]. RN7SL229P does not produce a functional RNA, is not expressed as a protein, and lacks documented biological or pathological significance. In rare cases, some pseudogenes act as competitive endogenous RNAs (ceRNAs) affecting gene regulation, but RN7SL229P is not known to have such a role[2][6]. Summary: RN7SL229P is a non-functional pseudogene derived from the 7SL RNA gene family, not a recognized therapeutic target or disease-associated biomolecule, with no established biological functions, disease roles, or pharmacological relevance[1][2][6].

Other names
RN7SL229PRNA, 7SL, cytoplasmic 229, pseudogene
02

Mechanism of action

None. RN7SL229P does not encode a functional molecule amenable to a therapeutic mechanism of action.

03

Biological functions

None established. Pseudogenes typically lack direct biological function, although some have regulatory effects (such as acting as miRNA sponges) in other cases. There is no documentation of such functions for RN7SL229P.
04

Disease associations

None known. The general class of pseudogenes can sometimes be implicated in disease via gene regulation, but RN7SL229P itself is not known to have a role in cancer, inflammation, neurodegenerative disease, cardiovascular disease, infection, or other pathology.
05

Safety considerations

None. As a non-expressed pseudogene, there are no known safety concerns or therapeutic challenges related to targeting RN7SL229P.
06

Interacting drugs

None known or documented. No drugs have been reported to interact with RN7SL229P, nor does it encode a protein or functional RNA that could bind a drug.
07

Biomarkers

None reported for patient selection or efficacy monitoring.

Beyond the preview

Go deeper on RNA, 7SL, cytoplasmic 229, pseudogene (RN7SL229P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, 7SL, cytoplasmic 229, pseudogene (RN7SL229P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call